Roivant Sciences (ROIV) Asset Utilization Ratio (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Asset Utilization Ratio came in at 0.01 in Q4 2025, down 37.35% YoY from 0.01 in Q4 2024, and up 2.31% on a QoQ basis from 0.01 in Q3 2025.
Roivant Sciences (ROIV) Asset Utilization Ratio (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 5 years of Asset Utilization Ratio data on file, last reported at 0.01 in Q4 2025.
- Quarterly Asset Utilization Ratio fell 37.35% year-over-year to 0.01 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.01 (down 37.35% YoY) and the FY2026 annual result came in at 0.0, down 70.8% from the prior year.
- Asset Utilization Ratio advanced to 0.01 in Q4 2025, from 0.01 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.04 in Q4 2022 to a low of 0.01 in Q3 2025.
- A 5-year average of 0.02 and a median of 0.01 in 2021 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio surged 328.11% — and 2024, when it tumbled 81.64%.
- Tracing ROIV's Asset Utilization Ratio over 5 years: stood at 0.02 in 2021, then soared by 75.88% to 0.04 in 2022, then tumbled by 59.67% to 0.02 in 2023, then sank by 45.63% to 0.01 in 2024, then plunged by 37.35% to 0.01 in 2025.
- The last three Asset Utilization Ratio figures came in at 0.01 (Q4 2025), 0.01 (Q3 2025), and 0.01 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 0.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.00 |
| Dec 31, 2025 | 0.01 |
| Sep 30, 2025 | 0.01 |
| Jun 30, 2025 | 0.01 |
| Dec 31, 2024 | 0.01 |
| Sep 30, 2024 | 0.01 |
| Jun 30, 2024 | 0.01 |
| Dec 31, 2023 | 0.02 |
| Sep 30, 2023 | 0.03 |
| Jun 30, 2023 | 0.03 |
| Dec 31, 2022 | 0.04 |
| Sep 30, 2022 | 0.03 |
| Jun 30, 2022 | 0.03 |
| Dec 31, 2021 | 0.02 |
| Sep 30, 2021 | 0.01 |
| Jun 30, 2021 | 0.01 |